 SUNNYVALE, Calif., Dec. 22, 2022 GLOBE NEWSWIRE BioCardia, Inc. Nasdaq: BCDA, a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders: Dear Shareholders,BioCardia is now advancing four novel cell therapies, with three focused on heart disease, a leading cause of death and reduced ... The post BioCardia Letter to Shareholders appeared first on ForexTV... 